Quanterix Corporation

Canaccord Genuity acts as Co-Manager for upsized US$97.6 million public offering of common stock by Quanterix Corporation

Canaccord Genuity is pleased to announce that on August 11, 2020, it completed a public offering of common stock for 

Quanterix Corporation (NASDAQ: QTRX) (the “Company”). The Company issued a total of 3,048,774 shares of its common stock at a price to the public of $32.00 per share, which includes the full exercise of the underwriters’ overallotment option. The gross proceeds to the Company, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately $97.6 million. The Company intends to use the net proceeds from the offering to expand commercial operations, improve technology and instruments, pursue regulatory approvals to develop products, for acquisitions or other business development opportunities and for working capital and general corporate purposes, including capital expenditures, investments and collaborations.

Canaccord Genuity acted as Co-Manager for the offering.

Quanterix Corporation develops next generation, ultra-sensitive digital immunoassay platforms that advance precision health. The Company’s technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve quality of life and longevity for patients.